To order this 310+page report, which features 150+ figures and 200+ tables, please visit this link
Key Market Insights
§ Many small / macro molecule-based STING pathway modulators are currentlybeing evaluated as monotherapies as well as in combination with other drugs
§ The pipeline features candidates targeting differenttherapeutic areas and designed for administration through a variety of routes;majority of such therapeutics are being developed as third-line and second-linetreatments
§ In recent years, several well funded start-ups have enteredthis field of research, and are gradually developing proprietary products basedon the STING pathway for the treatment of a variety of indications
§ In addition, a number of big pharmaceutical players havealso partnered with developers focused on STING targeting molecules in order toexpand their respective capabilities in this upcoming field of pharmacology
§ Published scientific literature indicates that bothindustry and academic players have made equal contributions to the innovationin this field; the major focus of such studies is presently on anti-cancertherapeutics
§ Several non-profit organizations have extended financialsupport to aid research efforts in this domain; the current focus appears to beon drug development and disease modelling studies
§ Foreseeing a lucrative future, private and public investorshave invested capital worth over USD 2.5 billion, across more than 80instances, in companies involved in STING pathway research
§ The rising interest is also reflected in recent partnershipactivity, involving the active participation of both international andindigenous companies; majority of the deals have been focused on noveltechnology platforms
§ Multiple companies are developing novel technologyplatforms for enhancing the research and development of STING pathway targetingtherapeutics
§ Technology developers are expected to continue relying onlicensing agreements involving different STING modulators as their primarysource of revenues in the foreseen future
For more information, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html
Table of Contents
1. PREFACE
1.1. Scopeof the Report
1.2. ResearchMethodology
1.3. KeyQuestions Answered
1.4. ChapterOutlines
2. EXECUTIVESUMMARY
3.1. Stimulator of Interferon Genes(STING) Pathway
3.2. STING Signaling
3.2.1. Relevance in Cancer
3.2.2. Relevance in Autoimmune Diseases
3.2.3. Relevance in Antimicrobial HostDefense
3.3. STING Pathway Modulators
3.3.1. STING Agonists
3.3.2. STING Antagonists
3.3.3. STING Activating Drug DeliverySystems
3.3.4. Indirect STING Activating Therapies
3.4. Key Variants of STING
3.5. Non-immunological Functions of theSTING Pathway
3.6. Concluding Remarks
4. STING PATHWAY TARGETINGTHERAPEUTICS: CURRENT MARKET LANDSCAPE
4.1. ChapterOverview
4.2. STINGPathway Targeting Therapeutics: Development Pipeline
4.2.1. Analysisby Type of STING Modulator
4.2.2. Analysisby Type of Molecule
4.2.3. Analysisby Phase of Development
4.2.4. Analysisby Therapeutic Area
4.2.5. Analysisby Type of Therapy
4.2.6. Analysisby Route of Administration
4.2.7. Analysisby Line of Treatment
4.3. STINGPathway Targeting Therapeutics: Developer Landscape
4.3.1. Analysisby Year of Establishment
4.3.2. Analysisby Company Size
4.3.3. Analysisby Geography
4.3.4. MostActive Players
4.4. STINGPathway Targeting Therapeutics: List of Clinical Trials
4.4.1. Analysisby Trial Recruitment Status
4.4.2. Analysisby Study Design
4.4.3. Analysisby Key Clinical Endpoints
5. STING PATHWAY TARGETINGTECHNOLOGIES: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. STING Pathway TargetingTechnologies: List of Technology Developers
5.2.1. Analysis by Type of Modulator
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Year of Establishment
5.2.4. Analysis by Company Size
5.2.5. Analysis by Geography
6. COMPANY PROFILES
6.1. ChapterOverview
6.2 STINGAgonist Developers
6.2.1. AduroBiotech
6.2.1.1. CompanyOverview
6.2.1.2. FinancialInformation
6.2.1.3. ProductDescription: ADU-S100 (MIW815)
6.2.1.4. RecentDevelopments and Future Outlook
6.2.2. Bristol-MyersSquibb
6.2.2.1. CompanyOverview
6.2.2.2. FinancialInformation
6.2.2.3. ProductDescription: BMS-986301
6.2.2.4. RecentDevelopments and Future Outlook
6.2.3. Eisai
6.2.3.1. CompanyOverview
6.2.3.2. FinancialInformation
6.2.3.3. ProductDescription: E7766
6.2.3.4. RecentDevelopments and Future Outlook
6.2.4 GlaxoSmithKline
6.2.4.1. CompanyOverview
6.2.4.2. FinancialInformation
6.2.4.3. ProductDescription: GSK3745417
6.2.4.4. RecentDevelopments and Future Outlook
6.2.5. ImmuneSensorTherapeutics
6.2.5.1. CompanyOverview
6.2.5.2. ProductDescription: IMSA101
6.2.6. Merck
6.2.6.1. CompanyOverview
6.2.6.2. FinancialInformation
6.2.6.3. ProductDescription: MK-1454 and MK-2118
6.2.6.4. RecentDevelopments and Future Outlook
6.2.7. Noxopharm
6.2.7.1. CompanyOverview
6.2.7.2. ProductDescription: NOX66
6.2.7.3. RecentDevelopments and Future Outlook
6.2.8. SpringBank Pharmaceuticals
6.2.8.1. CompanyOverview
6.2.8.2. FinancialInformation
6.2.8.3. ProductDescription: SB 11285
6.2.8.4. RecentDevelopments and Future Outlook
6.2.9. Synlogic
6.2.9.1. CompanyOverview
6.2.9.2. FinancialInformation
6.2.9.3. ProductDescription: SYNB1891
6.2.9.4. RecentDevelopments and Future Outlook
6.3. STINGAntagonist Developers
6.3.1 AvammuneTherapeutics
6.3.2. Curadev
6.3.3 ImmuneSensorTherapeutics
6.3.4. NimbusTherapeutics
6.3.5. Sirenas
6.3.6. SpringBank Pharmaceuticals
6.3.7. STINGINN
6.3.8. STipeTherapeutics
7 ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. STING Pathway TargetingTherapeutics: List of Academic Grants
7.3.1. Analysis by Number of Grants
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Funding Institute
7.3.4. Analysis by Support Period
7.3.5. Analysis by Funding Mechanism
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Grant Activity Code
7.3.8. Analysis by Funding Institutes
7.3.9. Analysis by Type of RecipientOrganization
7.3.10 Regional Distribution of GrantRecipients
7.3.11 Most Popular Recipient Organizations:Analysis by Number of Grants and Amount Invested
7.3.12. Prominent Project Leaders: Analysis byNumber of Grants
7.3.13 Analysis by Support Year and AmountAwarded
7.3.14. Analysis by Study Section
7.4. Grant Attractiveness Analysis
8 STING RELATED INITIATIVES OFBIG PHARMACEUTICALS PLAYERS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Initiatives Undertaken by BigPharma Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Type of Molecule
8.3.3. Analysis by Phase of Development
8.3.4. Analysis by Therapeutic Area
8.3.5. Analysis by Type of Therapy
8.3.6. Analysis by Route of Administration
8.4. Benchmarking Big Pharma Players
8.4.1 Spider Web Analysis: AbbVie
8.4.2. Spider Web Analysis: Bayer
8.4.3. Spider Web Analysis: Bristol-MyersSquibb
8.4.4. Spider Web Analysis: Celgene
8.4.5. Spider Web Analysis: Eisai
8.4.6. Spider Web Analysis: Eli Lily
8.4.7. Spider Web Analysis: Genentech
8.4.8. Spider Web Analysis: GlaxoSmithKline
8.4.9. Spider Web Analysis: Merck
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: TakedaPharmaceuticals
9 START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Type of Molecule
9.3.3. Analysis by Phase of Development
9.3.4 Analysis by Therapeutic Area
9.3.5. Analysis by Funding Amount
9.3.6. Analysis by Number of Investors
9.3.7. Analysis by Type of Funding
9.3.8. Analysis by Partnership Activity
9.3.9. Analysis by Other Parameters
9.3.10. Analysis by Location of Headquarters
9.3.11. Start-up Health Indexing: Roots AnalysisPerspective
10 PUBLICATION ANALYSIS
10.1. ChapterOverview
10.2. Scopeand Methodology
10.3. STINGPathway Targeting Therapeutics: Recent Publications
10.3.1. Analysisby Type of Publication
10.3.2. Analysisby Type of Publication and Year
10.3.3. Analysisby Study Objective
10.3.4. Analysisby Popular Keywords
10.3.5. Analysisby Type of STING Modulator
10.3.6. Analysisby Target Pathway
10.3.7. Analysisby Therapeutic Area
10.3.8. Analysisby Type of STING Modulator and Therapeutic Area
10.3.9 Analysis by Type of Publisher
10.3.10. Leading Players: Analysis by Number ofPublications
10.3.11. Leading Players: Geographical Analysis byNumber of Publications
10.3.12. Analysisby First Author Organization
10.3.13. KeyJournals: Analysis by Number of Publications
11 PARTNERSHIPSAND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. STING Pathway TargetingTherapeutics: Recent Partnerships
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3 Analysis by Type of STING Modulator
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Technology Platform
11.3.6. Most Active Players: Analysis by Numberof Partnerships
11.3.7. Geographical Analysis
11.3.7.1 Most Active Players: Analysis by Numberof partnerships
11.3.7.2. Intercontinental and IntracontinentalAgreements
12. FUNDINGAND INVESTMENT ANALYSIS
12.1. ChapterOverview
12.2. Typesof Funding
12.3. STINGPathway Targeting Therapeutics: Recent Funding Instances
12.3.1. Analysisby Number of Funding Instances
12.3.2. Analysisby Amount Invested
12.3.3. Analysisby Type of Funding
12.3.4. Analysisby Type of STING Modulator
12.3.6. Analysisby Therapeutic Area
12.3.6 Analysisby Amount Invested and Type of STING Technology Platform
12.3.7. MostActive Players: Analysis by Number of Funding Instances
12.3.8. MostActive Investors: Analysis by Number of Funding Instances
12.3.9. GeographicalAnalysis by Amount Invested
12.4. ConcludingRemarks
13. MARKET SIZING AND OPPORTUNITYANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and ForecastMethodology
13.3. Global STING Pathway TargetingTechnologies Market, 2020-2030
13.3.1. STING Pathway Targeting TechnologiesMarket by Upfront Payments, 2020-2030
13.3.2. STING Pathway Targeting TechnologiesMarket by Milestone Payments, 2020-2030
13.3.3. STING Pathway Targeting TechnologiesMarket: Distribution by Type of STING Modulator
13.3.3.1. STING Pathway Targeting TechnologiesMarket for Agonist, 2020-2030
13.3.3.2. STING Pathway Targeting TechnologiesMarket for Antagonist, 2020-2030
13.3.4. STING Pathway Targeting TechnologiesMarket: Distribution by Therapeutic Area
13.3.4.1. STING Pathway Targeting TechnologiesMarket for Oncological Disorders, 2020-2030
13.3.4.2. STING Pathway Targeting TechnologiesMarket for Inflammatory Disorders, 2020-2030
13.3.4.3. STING Pathway Targeting TechnologiesMarket for Infectious Diseases, 2020-2030
13.3.4.4. STING Pathway Targeting TechnologiesMarket for Other Therapeutic Areas, 2020-2030
13.3.5. STING Pathway Targeting TechnologiesMarket: Distribution by Route of Administration
13.3.5.1. STING Pathway Targeting TechnologiesMarket for Intratumoral Route, 2020-2030
13.3.5.2. STING Pathway Targeting TechnologiesMarket for Intravenous Route, 2020-2030
13.3.5.3. STING Pathway Targeting TechnologiesMarket for Oral Route, 2020-2030
13.3.5.4. STING Pathway Targeting TechnologiesMarket for Subcutaneous Route, 2020-2030
13.3.5.5. STING Pathway Targeting TechnologiesMarket for Other Routes, 2020-2030
13.3.6. STING Pathway Targeting TechnologiesMarket: Distribution by Type of Molecule
13.3.6.1. STING Pathway Targeting TechnologiesMarket for Non-Nucleotide, 2020-2030
13.3.6.2. STING Pathway Targeting TechnologiesMarket for Cyclic Dinucleotide, 2020-2030
13.3.6.3. STING Pathway Targeting TechnologiesMarket for Live Biotherapeutics, 2020-2030
13.3.6.4. STING Pathway Targeting TechnologiesMarket for Oncolytic Viruses, 2020-2030
13.3.6.5. STING Pathway Targeting Technologies Marketfor Synthetic Peptides, 2020-2030
13.3.6.6. STING Pathway Targeting TechnologiesMarket for Other Molecules, 2020-2030
13.3.7. STING Pathway Targeting TechnologiesMarket: Distribution by Geography
13.3.7.1. STING Pathway Targeting TechnologiesMarket in North America, 2020-2030
13.3.7.2. STING Pathway Targeting TechnologiesMarket in Europe, 2020-2030
13.3.7.3. STING Pathway Targeting TechnologiesMarket in Asia-Pacific, 2020-2030
14. EXECUTIVEINSIGHTS
15. CONCLUDING REMARKS
15.1. Chapter Overview
15.2. Key Takeaways
16. APPENDIX1: TABULATED DATA
17. APPENDIX2: LIST OF COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
